Tab Title Description
The purpose of this study is Bioprosthetic valve thrombosis (BPVT) can be predicted in a prospective cohort of patients undergoing transcatheter aortic valve replacement (TAVR) Implementation of pharmacogenetics counselling can prevent major clinical bleeds in patients undergoing TAVR
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
Adult patients with severe aortic valve disease
Scheduled to undergo TAVR at Mayo Clinic for clinical indication
Intended follow-up for TAVR at Mayo Clinic during the first 18 months after TAVR
Willing and able to provide informed consent
Exclusion Criteria:
Inability to provide informed consent
Follow-up planned at outside institution
Note: Other protocol defined Inclusion/Exclusion Criteria may apply.
Eligibility last updated 04/22/2026. Questions regarding updates should be directed to the study team contact.
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
Mayo Clinic principal investigator
Bastiaan Kietselaer, M.D., Ph.D.
Open for enrollment
Structural Heart Disease Research Coordinators
(507) 255-6133